Tests problem-solving training for nausea during oral chemotherapy in children
Tests problem-solving skill training for nausea in children with leukemia taking oral chemotherapy.
Plain-language title generated from the registry record
Registry title: Bright Ideas - CIN Feasibility Study
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 18 years old?
Source: NCT04929899, who can take part
Where in Canada
- Hospital for Sick ChildrenToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Hospital for Sick Children
- Trial code
- NCT04929899
- Record updated
- 31 January 2025
- Original description
In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.Read full original descriptionShow less
Improving Chemotherapy-induced Nausea Control Through Bright Ideas®-CIN Training: a Feasibility Study in Children Receiving Oral Chemotherapy
In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.
Inclusion: Age: ≥ 4 years (PeNAT validated in patients 4 to 18 yrs); newly diagnosed or recurrent disease: first diagnosis of ALL (i.e. non-relapsed) in maintenance therapy; English, French or Spanish-speaking with an English, French or Spanish-speaking guardian (PeNAT available in these languages); without physical or cognitive impairments that preclude use of the PeNAT; planned to receive PO 6-mercaptopurine; not planned to receive IV, IM, SC or IT chemotherapy or oral or IV corticosteroids during the 7-day study period.